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Introduction 
Previously1 we have discussed the diagnosis, 
classification and prevention of diabetes mellitus.  In 
this article we provide an overview of management 
of glycaemic control in diabetes mellitus as well as 
managing hypoglycaemia.  We also look at the 
management of diabetic complications and provide a 
basis by which to run a diabetes clinic. 
Glycaemic control 
Control of glycaemia leads to a reduction in both 
macrovascular and microvascular complications.  
There are several methods by which this can be 
done. 
General measures 
All patients with diabetes are treated with dietary 
modification.  There is nothing special about a 
‘diabetic diet’ and patients with diabetes should be 
advised to eat the same healthy diet as promoted to 
the non-diabetic population.  Likewise, patients with 
diabetes should be encouraged to participate in 
regular exercise of the kind that would benefit the 
rest of the population.  Most patients with new onset 
type 2 diabetes should initially be managed with 
dietary modification (and exercise) alone although 
there is now a trend towards early use of metformin 
(see below). 
 
Type 1 diabetes 
All patients with type 1 diabetes are treated with 
exogenous insulin and there are many different types 
of insulins available, all of which have different 
profiles.  Two main insulin regimens are commonly 
used.   
 A twice daily administration of pre-mixed insulin 
which contains a mixture of short acting and 
longer acting insulins in a ratio between 30:70 to 
50:50.   
 A “basal-bolus” regimen in which the patient 
takes the longer acting (basal) insulin at night 
and the shorter acting (bolus) insulin with each 
meal.   
There is no one correct regimen and choice depends 
on patient preference, education and available 
support as well as availability of treatment options.  
In all situations patient education is vital as they are 
responsible for their own individual day-to-day 
management.  Advice for storing and using insulin 
are included in the appendix and the plasma insulin 
levels achieved with basal-bolus and twice daily 
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Figure 1:  Basal‐Bolus  Regime
Plasma insulin concentrations over time with a basal bolus insulin regime
F igure 2: P remixed twice daily regime
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Plasma insulin concentrations over time with a twice daily insulin mix 
regime
Special considerations in type 1 diabetes - sick day 
rules: 
 When ill, blood glucose levels may rise above 
normal even if patients are not able to eat 
normal meals or drink anything, so NEVER 
STOP INSULIN. 
 Test blood glucose levels approximately every 4 
hours and adjust dose of insulin.  
Hypoglycaemia is common in malarial illnesses 
both because of the disease and also potentially 
as a result of drugs used in its treatment (e.g. 
quinine or mefloquine) so very frequent 
monitoring is advised and insulin dose 
reductions may be necessary.  
 To prevent dehydration encourage the patient to 
drink 2-3 litres of sugar free liquids per day. This 
is approximately one glass every hour. 
 If the patient is vomiting or unable to eat solid 
carbohydrate foods replace this with liquid 
carbohydrates such as fruit juice, sugary drinks. 
Type 2 Diabetes 
Oral hypoglycaemic agents 
 Metformin reduces blood glucose levels by 
decreasing hepatic glucose output and increasing 
peripheral glucose uptake and utilisation in 
insulin sensitive tissues. It is the mainstay of 
treatment in obese individuals with type 2 
diabetes and can be used alone or in 
combination with other medications including 
sulphonylureas and insulin.  Approximately one-
third of patients on metformin will have 
transient nausea, anorexia or diarrhoea, 
abdominal discomfort, and metallic taste.  These 
side effects can be minimised by starting with a 
low dose (e.g. 500 mg daily with the main meal) 
gradually increasing the dose up to a maximum 
of 2 g per day in divided doses.  The main 
limitation to metformin use is the risk of 
developing the potentially fatal complication of 
lactic acidosis. This is higher in individuals with 
either renal (creatinine >130-150 micromol/l), 
cardiac or hepatic failure where either the 
metabolism of metformin is impaired or lactate 
production is increased. Metformin must be 
used with caution or stopped in these 
individuals.  Also be aware that chronic 
metformin use can lead to Vitamin B12 
deficiency.   
 Sulphonylureas (Gliclazide, Glibenclamide, 
Glipizide, Tolbutamide) increase the pancreatic 
release of insulin and are used to treat patients 
with type 2 diabetes who have adequate insulin 
reserve.  Because of their tendency to promote 
weight gain, they are best used as first line agents 
in non-obese patients but may be added to 
metformin in obese patients with inadequate 
control.  The main side-effect associated with 
this class of medication is hypoglycaemia and all 
patients need to be warned of this possibility. 
 Thiazolidinediones are also insulin sensitizing 
agents.  They are second-line agents that can be 
used in combination with metformin and 
sulphonylureas but are contraindicated in 
individuals with ischaemic heart disease, cardiac 
failure, severe renal insufficiency, pregnancy, 
breastfeeding and hepatic dysfunction.  The 
most significant side effect is weight gain mainly 
due to fluid retention. 
 
Insulin in type 2 diabetes  
Patients with type 2 diabetes require treatment with 
insulin on average 7 years after diagnosis.  Insulin 
treatment of patients who are already overweight or 
obese carries the risk of inducing further weight gain.  
Unfortunately this can lead to further increases in 
insulin requirements and more weight gain.  
However, as these patients do not usually require 
exogenous insulin action throughout the 24 hour 
period other regimes may be considered, particularly 
addition of once-daily longer acting insulin (e.g. 
NPH insulin, insulin glargine or insulin detemir) in 
combination with oral hypoglycaemic agents.  
Plasma insulin concentrations achieved with once 
daily intermediate acting insulin is illustrated in figure 
3.  The main limitation to insulin use is 
hypoglycaemia.   
 
Most patients with type 2 diabetes, especially those 
who are overweight, should remain on metformin 
when insulin is instituted/started in whatever form 
unless there are contraindications to its use.  
Hypoglycaemia 
Hypoglycaemia is the commonest complication of 
type 1 diabetes and is frequent in type 2 diabetes 
with insulin or sulphonylureas. Always try to find out  
 
 
the cause of any hypoglycaemia as it will determine 
future management. Common causes include: 
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F igure 3:  Once daily regime
Plasma insulin concentrations over time with a once daily 
intermediate acting insulin regime
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 Malaria 
 Dietary – missing or delaying a meal 
 Too much insulin: inadvertent administration 
 Unaccustomed exercise 
 Alcohol/recreational drugs 
 Over dosage of sulphonylureas. 
 
Symptoms can be classified as: 
 early autonomic symptoms: sweating, shaking, 
palpitations, hunger, nausea 
 later neuroglycopaenic symptoms: confusion, 
poor concentration, and co-ordination 
Occasionally seizures or localising signs such as 
hemiparesis occur. 
The risk of hypoglycaemia provides the main 
limitation to the achievement of good glycaemic 
control in diabetes.  Effects may be devastating, 
permanent and may occur over minutes or hours.  
Some 2-4% of deaths in type 1 diabetes are thought 
to be due to hypoglycaemia.   
Patient education and recognition of hypoglycaemia 
with appropriate management is an important aspect 
of diabetes management. In the event of 
symptomatic hypoglycaemia or a blood glucose 
72g/dl (<4mmol/l) treat with 20g of fast acting oral 
carbohydrate (3-4 cubes sugar/glucose tablets) 
followed up with a longer acting carbohydrate 
(bread, biscuits).  In the event of severe 
hypoglycaemia the patient may be unable to help 
themselves and management includes intravenous 
glucose (20-30ml of 50% dextrose) repeated as 
necessary or glucagon (1mg im, iv or sc). Both of 
these treatments need following up with further oral 
or iv carbohydrate depending on response with 
ongoing capillary glucose monitoring until stable. 
Complications 
The many complications related to diabetes mellitus 
can be divided into: 
 macrovascular – stroke, MI, peripheral vascular 
disease 
 microvascular – nephropathy, retinopathy, 
neuropathy.   
 
To achieve good glycaemic control aim for blood 
glucose values to be: 
 70-125 g/dl (4-7mmol/l) fasting,  
 <140g/dl (7.8mmol/l) post prandial,  
 <35g/dl (2 mmol/l) with prandial excursions;  
or ideally an HbA1c of 6.5-7.5% (48-59mmol/mol).   
Ideally blood pressure should be < 140/80 mmHg 
but patients with nephropathy may benefit from 
even tighter control e.g. 130/70 mmHg.   
Lipid control in type 2 diabetes usually requires an 
HMG CoA Reductase Inhibitor e.g. simvastatin 40 
mg od to achieve target LDL levels of below 2-3 
mmol/l.  Some advocate the addition of a fibrate 
such as fenofibrate if triglyceride remains elevated 
(e.g. above 2.3-2.8 mmol/l.) 
Nephropathy 
Prolonged hyperglycaemia leads to glomerular 
hyperfiltration which eventually can lead to 
proteinuria.  A stage of microalbuminuria is 
detectable by laboratory analysis of urine before a 
urine dipstick becomes positive for proteinuria 
(which almost always preceeds a fall in renal 
function). Good glycaemic control with aggressive 
blood pressure control (<130/80) and use of ACE-
Inhibitors or Angiotensin II receptor blockers can 
delay the progression of microalbuminuria to 
proteinuria.  Other causes of renal failure (e.g. 
stones, infections, renovascular disease) should be 
considered if there is no evidence of proteinuria or 
retinopathy: diabetic nephropathy without 
retinopathy is almost unheard of. 
Eye disease (retinopathy) 
This is a common cause of blindness worldwide and 
after 15 years of diabetes about 2% of people are 
blind with 10% having severe visual impairment. In 
addition, cataracts and glaucoma are more common 
in people with diabetes.  There are 2 main stages of 
diabetic retinopathy: 
 pre-proliferative (almost always asymptomatic) 
 microaneurysms and small haemorrhages visible 
on retina 
 proliferative (usually asymptomatic but can cause 
blurring or reduced vision and dark spots) 
 new vessel formation on retina and optic disc 
with risk of retinal detachment. 
Maculopathy is another significant complication 
caused by reduced blood supply to the macula which 
in turn leads to macular oedema and blindness. 
There is no treatment for the early stages of diabetic 
retinopathy and prevention is achieved by good 
glycaemic and blood pressure control.  Later stages 
of retinopathy can be treated with laser therapy by 
experienced specialists. Ideally all diabetic patients 
should have annual retinal examinations. 
Neuropathy 
Almost any neuropathy can be caused by diabetes 
and may be focal (e.g. cranial and peripheral 
mononeuropathies), diffuse (e.g. painful sensory 
neuropathy) or autonomic. Alternative diagnoses 
must always be considered as patients are at risk of 
neuropathies of other cause (e.g. thyroid 
dysfunction, B12 deficiency, vasculitis, malignancy, 
drugs, alcohol, infection). There are no specific 
treatments for diabetic neuropathies but most will 
respond to improved glycaemic control, sometimes 
with insulin.  Pain can be treated with simple 
analgesics initially although they are not always 
successful and medications such as amitriptyline (e.g. 
10mg od) or gabapentin can be tried.  
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Mononeuropathies will usually resolve spontaneously 
over 6-24 months.   
Diabetic foot disease 
This is a complex pathological process in which the 
culmination of vasculopathies and neuropathies 
associated with the poor wound healing of diabetes 
can lead to foot ulceration, infection and ultimately 
amputation.  Routine foot examination is an 
important part of preventing this potentially fatal 
complication and should be performed regularly by 
all patients.  The presence of callus often implies 
abnormal loading and high risk for ulceration.  
Simple advice includes: 
1. Look carefully at the feet each day including in 
between the toes for signs of infection or 
deformity.  If the patient is unable to do this 
then someone should do it for them.  
2. Cut nails following the curvature of the toe. 
3. Wash feet regularly and dry carefully. 
4. Try to avoid walking barefoot. 
5. Wear well-fitting footwear. 
 
 
Use this checklist when assessing the foot: 
1. Inspection – colour, shape, hard skin, cracked 
skin, ulcers, hair distribution 
2. Palpation – pulses (dorsalis pedis and posterior 
tibial), warmth, capillary refill time 
3. Assessment of protective sensation (10g 
monofilament, vibration sense, light touch 
perception). 
Treatment measures include appropriate treatment 
of infections with anti-microbial therapy (e.g. 
flucloxacillin as 1st line therapy but directed as 
appropriate to suspected or cultured organism) and 
the ulcer base should be debrided of any non-viable 
tissue as appropriate.  Equally important is 
appropriate footwear with offloading any pressure 
on the affected area and appropriate dressings in 
order to prevent further infection/ulceration.  
Hyperglycaemia over around 200g/dl (11.1 mmol/l) 
is associated with marked reduction in immune 
function and tissue repair and should be tackled 
where possible. 
Running a diabetes service 
When setting up a diabetes clinic ideally all people with diabetes have an annual review with interim visits guided 
by the availability of access, presence/absence of complications, glycaemic control and patient choice. 
In Table 1 we provide a checklist for covering what should be addressed at each annual review.  Specifics need to 
be targeted to each individual as appropriate.  
 
Table 1. What to do at a patient’s annual review 
HISTORY  
General medical and non medical events  
Specific problems   
Problems with diabetes treatment e.g. assessment of adherence, side effects, interactions etc. 
Problems with other treatment e.g. assessment of adherence, side effects, interactions etc.  
Glycaemic control Barriers to, treatment for, understanding of, goal setting for, 
fasting, postprandial, other 
Hypoglycaemia Frequency, severity, awareness, precipitants, driving, 
acceptability, avoidance etc 
Education Sick day rules, hypoglycaemia, good control, foot care, 
specific issues, glycaemic control etc 
Lifestyle factors Diet, exercise, smoking, weight, other drugs, other factors 
Contraception/Conception Higher dose folic acid (5 mg) pre-conception.  Close 
antenatal care with tight glycaemic control to reduce risk of 
foetal anomalies, macrosomia etc 
Vascular risk assessment and treatment (e.g. 
?aspirin, ACE etc) 
Glycaemic control, microalbuminuria, smoking, BP, lipids, 
FH, duration of diabetes, FH of microvascular complications 
etc.  
Diabetes prevention Post GDM, family members, IGT etc.  
EXAMINATION  
Microvascular Complications Neuropathy (autonomic or peripheral), nephropathy, 
retinopathy, foot examination 
Macrovascular Complications Claudication, Stroke, amaurosis fugax, MI, angina 
Other complications Infections, bladder, bowel, muscle, cognitive etc.  
Erectile Dysfunction Detection, ask, differential diagnosis, testosterone, prolactin, 
treatments for etc 
Injection sites Inspect for lipoatrophy or hypertrophy 
BLOOD AND OTHER TESTS  
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BP Postural hypotension, pulse (autonomic neuropathy) 
Urine dipstick Proteinuria, haematuria, glycosuria, infection 
Blood tests Creatinine, HbAlc, Lipids, LFTs, TFTs, Autoantibodies etc 
AGREED MANAGEMENT PLAN Specific targets and management plan for factors identified 
 
Appendix:  Advice for insulin usage 
1. Storage  - keep unopened vials/cartridges of insulin in the fridge until needed. Once open each vial/cartridge 
can be safely stored at room temperature for 1 month.  Insulin should not be exposed to extremes of 
temperature (very hot or very cold) as this will affect its action. 
2. Mixing –  pre-mixed insulins need to be rocked/rolled approximately 20 times until the mixture is uniformly 
cloudy before use to ensure the ratio administered is correct. 
3. Expiry – all insulin has an expiry date, do not use after this date as the action of the insulin cannot be 
guaranteed 
4. Changing needles – needles are designed for single use only and repeated use of needles reduces the accuracy 
of insulin administration.   
5. Needle disposal – all needles should be disposed of safely into a sharps bin.  If a sharps bin is not available a 
thick plastic bottle with a child-proof lid (e.g. empty bleach bottle) is a good substitute. 
 
Reference and further reading 
1. Lawrence V. 2009 Diabetes. Part 1. Definition, Diagnosis and Prevention Southern Sudan Medical Bulletin 2:2 p7 
The following on-line resources provide further information and links to other relevant sites:   
 American Diabetes Association (ADA) Clinical Practice Guidelines http://www.diabetes.org/ for-health-
professionals-and-scientists/cpr.jsp 
 ADA Guidelines on Diabetic Emergencies http://care.diabetesjournals.org/cgi/content/full/27/suppl_1/s94 
 National Diabetes Information Clearing House http://diabetes.niddk.nih.gov/ 
 
See also: 
Lancet special issue on diabetes 23 May 2009 Volume 373 Number 9677 
http://www.thelancet.com/journals/lancet/issue/current 
The editorial states, "…... Four-fifths of all patients with diabetes live in developing countries. Across Africa, the 
Middle East, and South and Central America, the prevalence of diabetes is estimated to rise by about 80% over 
the next 15 years.” It points out that research efforts in developed countries have produced effective screening 
and prevention programmes and drug treatments for the management of diabetes, but that “….little of this 
expertise is available in developing countries that are only now beginning to recognise the burden of chronic 
non-communicable diseases. …. Few diabetes drugs feature on essential drugs lists, and those countries that 
have access to insulin often store it at a central location, beyond the reach of the majority."  
Articles in this issue include: 
 A comprehensive meta-analysis showing that women with gestational diabetes have a seven-fold increased 
risk of subsequently developing type 2 diabetes compared with women with a normoglycaemic pregnancy 
(and an accompanying Seminar on gestational diabetes). 
 A meta-analysis suggesting that intensive glucose control can significantly reduce rates of adverse coronary 
events, without increasing the risk of death. 
 
HIV infection and diabetes A recent study shows that HIV infection itself does not increase the risk if 
diabetes. The results showed that at the start of the study, people with HIV had a lower risk of diabetes than 
HIV-negative individuals. However, this was because of the low body mass index (BMI) of untreated HIV-
positive individuals; an improving immune status, treatment with antiretroviral drugs, and hepatitis C virus were 
all shown to increase diabetes risk in people with HIV. There is general agreement that traditional risk factors for 
diabetes, such as increasing age, obesity, and race, are responsible for most cases of the condition diagnosed in 
people with HIV. What is less clear is the role of risk factors such as the use of antiretroviral drugs and co-
infection with hepatitis C virus. Butt AA. HIV infection and the risk of diabetes mellitus. AIDS 23: 1227-34, 2009. 
 
The Diabetes Foundation report on implementing national diabetes programmes in sub-Saharan Africa 
http://www.access2insulin.org/Diabetes_Foundation_report_on_implementing_national_diabetes_programmes_in_sub-
Saharan_Africa_full_report.pdf 
